| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2):87-108.
|
| [2] |
Early Breast Cancer Trialists' Collaborative Group(EBCTCG),Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials [J].Lancet,2011,378(9793):771-784.
|
| [3] |
Payandeh M, Sadeghi M, Sadeghi E. Differences in prognostic factors between early and late recurrence breast cancers [J]. Asian Pac J Cancer Prev,2015,16(15):6575-6579.
|
| [4] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials[J]. Lancet, 2012,379(9814):432-444.
|
| [5] |
Castle J, Shaker H, Morris K, et al. The significance of circulating tumour cells in breast cancer: a review [J]. Breast,2014,23(5):552-560.
|
| [6] |
Asworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death[J]. Aust Med J,1869,14:146-149.
|
| [7] |
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science,2013,339(6119):580-584.
|
| [8] |
Bae YK, Choi JE, Kang SH, et al. Epithelial-mesenchymal transition phenotype is associated with clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancer[J]. J Breast Cancer,2015,18(3):256-263.
|
| [9] |
Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing[J]. Cancer Res,2013,73(10):2965-2975.
|
| [10] |
Wicha MS. Cancer stem cells and metastasis: lethal seeds[J]. Clin Cancer Res,2006,12(19):5606-5607.
|
| [11] |
Moncharmont C, Levy A, Gilormini M, et al. Targeting a cornerstone of radiation resistance: cancer stem cell[J]. Cancer Lett, 2012,322(2):139-147.
|
| [12] |
Chen D, Bhat-Nakshatri P, Goswami C, et al. ANTXR1, a stem cellenriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer[J]. Cancer Res,2013,73(18):5821-5833.
|
| [13] |
Li M, Zhang B, Zhang Z, et al. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer[J]. Biomed Res Int, 2014,2014:981 261.
|
| [14] |
Sun YF,Yang XR,Zhou J,et al. Circulating tumor cells:advances in detection methods, biological issues, and clinical relevance[J]. J Cancer Res Clin Oncol,2011,137(8):1151-1173.
|
| [15] |
Hou HW, Warkiani ME, Khoo BL, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces[J]. Sci Rep, 2013,3:1259.
|
| [16] |
Beije N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the CellSearch system: The clinician's guide to breast cancer treatment?[J]. Cancer Treat Rev,2015,41(2):144-150.
|
| [17] |
Broersen LH, van Pelt GW, Tollenaar RA, et al. Clinical application of circulating tumor cells in breast cancer [J]. Cell Oncol (Dordr),2014,37(1):9-15.
|
| [18] |
Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization: moving toward personalized medicine[J]. Ann Transl Med,2014,2(11):108.
|
| [19] |
Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology[J]. Nature,2007,450(7173):1235-1239.
|
| [20] |
Payne RE, Wang F, Su N, et al. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients[J]. Br J Cancer,2012,106(11):1790-1797.
|
| [21] |
Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/DetectTM versus Veridex CellSearchTM system[J]. Int J Cancer, 2012,130(7):1590-1597.
|
| [22] |
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells,disease progression, and survival in metastatic breast cancer [J]. N Engl J Med,2004,351(8):781-791.
|
| [23] |
Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival [J]. Clin Cancer Res,2006,12 (14 Pt 1):4218-4224.
|
| [24] |
Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data[J]. Lancet Oncol,2014,15(4):406-414.
|
| [25] |
Lv Q, Gong L, Zhang T, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis[J]. Clin Transl Oncol,2016,18(3):322-330.
|
| [26] |
Dawson SJ, Tsui DM, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer [J]. N Engl J Med, 2013,368(13):1199-1209.
|
| [27] |
Shiomi-Mouri Y, Kousaka J, Ando T, et al. Clinical significance of circulating tumor cells(CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer [J]. Breast Cancer,2016,23(1):120-127.
|
| [28] |
Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer[J]. Clin Cancer Res,2006,12(21):6403-6409.
|
| [29] |
De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and[18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer[J]. J Clin Oncol,2009,27(20):3303-3311.
|
| [30] |
Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice [J]. Eur J Cancer,2014,50(13):2303-2308.
|
| [31] |
姜军. 乳腺癌的精准诊疗:临床发展新趋势[J/CD]. 中华乳腺病杂志:电子版,2014,8(2):78-80.
|
| [32] |
Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500[J]. J Clin Oncol,2014,32(31):3483-3489.
|
| [33] |
Helissey C, Berger F, Cottu P, et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase Ⅲtrial[J]. Cancer Lett,2015,360(2):213-218.
|
| [34] |
Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials[J]. Cancer Metastasis Rev, 2013,32(1/2):179-188.
|
| [35] |
Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? [J]. Ann Oncol,2014,25(12):2304-2313.
|
| [36] |
Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment—The dawn of personalized medicine[J]. Exp Cell Res,2014,320(1):1-11.
|
| [37] |
Kalia M. Biomarkers for personalized oncology: recent advances and future challenges [J]. Metabolism,2015,64(3 Suppl 1):S16-S21.
|
| [38] |
Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective,multicenter trial [J]. Breast Cancer Res Treat,2010,124 (2):403-412.
|
| [39] |
Wallwiener M, Hartkopf AD, Riethdorf S, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients[J]. BMC Cancer,2015,15:403.
|
| [40] |
Aqelaki S, Kalykaki A, Markomanolaki H, et al. Efficacy of lapatinib in therapy-resistant HER2 positive circulating tumor cells in metastatic breast cancer[J].PLoS One,2015,10(6):e0123683.
|
| [41] |
Ligthart ST, Bidard FC, Decraene C, et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer[J]. Ann Oncol, 2013,24(5):1231-1238.
|
| [42] |
闫继慈,郑新宇. 乳腺癌患者循环肿瘤细胞检测及其临床意义[J/CD]. 中华乳腺病杂志:电子版,2013,7(6):436-441.
|
| [43] |
Bidard FC, de Rycke Y, Asselain B, et al. CirCe T-DM1 phase II trial:Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with TDM1 [EB/OL]. [2015-11-16]. http:/ /cancerres.aacrjournals.org/content/74/19_Supplement/CT317.short.
|
| [44] |
Schramm A, Friedl TW, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer:concept of the DETECT study program[J]. Arch Gynecol Obstet,2016,293(2):271-281.
|
| [45] |
Mostert B, Sieuwerts AM, Kraan J, et al. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients [J]. Ann Oncol,2015,26(3):510-516.
|
| [46] |
Onstenk W, Sieuwerts AM, Weekhout M, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer[J]. Cancer Lett,2015,362(1):36-44.
|
| [47] |
Turner N, Pestrin M, Galardi F, et al. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?[J]. Cancers (Basel),2014,6(2):684-707.
|